Skip to main content

Group Aiming to Cure Follicular Lymphoma Awarded $2.25 Million

Web Exclusives - Lymphoma
"Group Aiming to Cure Follicular Lymphoma Awarded $2.25 Million" was originally published by Oncology Practice Management.

Three research projects that are studying different approaches to addressing follicular lymphoma (FL) are about to get a boost in funds thanks to $2.25 million in award funding from the Follicular Lymphoma Foundation (FLF), The Leukemia & Lymphoma Society (LLS), and the Institute for Follicular Lymphoma Innovation (IFLI), who have all partnered in their “Research United to Cure FL” initiative.1

According to a news release on the awards: “Research United to CURE Follicular Lymphoma combines the shared mission and efforts of three leading blood cancer foundations to support and drive scientific innovation and accelerate clinical trials in FL, bringing more effective therapies and, ultimately, a cure for FL closer to reality."

In the release, Mitchell Smith, MD, who is Chief Medical Officer of FLF, said: “By uniting our expertise and resources, we can enhance our research efforts and accelerate the development of new treatments. This powerful alliance brings us one step closer to finding a cure.”  

Lee Greenberger, PhD, who is Chief Scientific Officer of LLS, added: “We are incredibly excited about the innovative projects we’ve funded. Each of these groundbreaking research initiatives holds immense potential to transform the treatment landscape.” 

Michel Azoulay, MD, who is Chief Medical Officer of IFLI, echoed Greenberger’s sentiments, adding: “We are thrilled to unite with FLF and LLS to CURE-FL and are confident that this partnership will significantly accelerate innovative research. Our aim is to provide catalytic capital to develop new technology approaches and a Path to a Cure for patients suffering from follicular lymphoma.” 

According to the release, the first project, from Mark Murakami, MD, and other researchers from Dana-Farber Cancer Institute, is analyzing data from several clinical trials patients undergoing treatment with bispecific antibodies that target the lymphoma and surrounding cells. The research aims to study resistance patterns among lymphoma cells and potentially expose vulnerabilities within the cells that can be exploited by novel combination treatments. 

A second project, led by Steven Park, MD, and his team at Atrium Wake Forest Levine Cancer, is looking at a targeted blood cancer strategy that focuses on using high-precision, targeted nanoparticles designed to deliver drugs only to the cancer, and designing specific protein-degrading chimeric molecules (PROTACs) that target a cancer-specific protein. They will use mantle cell lymphoma and FL as their test models. 

Also with this award, Philippe Armand, MD, and researchers from Dana-Farber Cancer Institute will be awarded funds for their project, which is investigating the efficacy of a bispecific antibody as a first-line treatment for FL patients. The investigators aim to identify biomarkers to predict how patients will respond to and tolerate bispecific antibody treatment in the absence of first-line chemotherapy.

Reference

  1. Leukemia & Lymphoma Society. Blood cancer foundations award $2.25 million for “Research United to Cure Follicular Lymphoma.” News release. August 7, 2024. Accessed August 14, 2024. https://www.lls.org/news/blood-cancer-foundations-award-225-million-research-united-cure-follicular-lymphoma
Related Items
Safety and Efficacy of Novel ADVD Regimen in an Adult Patient With Early-Stage Hodgkin Lymphoma and Hypoplastic Left Heart Syndrome: Case Report
JHOP - December 2024 Vol 14, No 6 published on December 5, 2024 in Case Reports, Lymphoma, Chemotherapy
Obinutuzumab Use After Serum Sickness in a Patient With Follicular Lymphoma: A Case Report
JHOP - October 2024 Vol 14, No 5 published on October 11, 2024 in Case Reports, Lymphoma, Adverse Events, Monoclonal Antibodies, Biosimilars
Triamterene Cross-Reactivity With Methotrexate Immunoassay: Case Report of Falsely Delayed Methotrexate Clearance During Treatment of High-Grade B-Cell Lymphoma
JHOP - April 2024 Vol 14, No 2 published on April 17, 2024 in Case Reports, Lymphoma, Adverse Events, Methotrexate
Economic Burden of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the First Year After Initiating Treatment with a Novel Agent
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in Original Research, Leukemia, Lymphoma, Adverse Events
Anakinra Used in a Patient with Diffuse Large B-Cell Lymphoma and Steroid-Refractory Immune Effector Cell–Associated Neurotoxicity Syndrome: Case Report
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in Case Reports, Lymphoma, CAR T-Cell Therapy, Adverse Events
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Updates, CAR T-Cell Therapy, Lymphoma
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Updates, Lymphoma, CAR T-Cell Therapy
Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Lymphoma, CAR T-Cell Therapy
Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies
Christopher Sinoimeri, PharmD, Bryan Do, PharmD, BCOP, Sheree Chen, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Original Research, Lymphoma, Immunotherapy, Infections, Monoclonal Antibodies
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma